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Abstract
The ductus arteriosus (DA) is a shunt vessel between the aorta and the pulmo-
nary artery during the fetal period. It is well recognized that prostaglandin E2
(PGE2) dilates the DA through activation of its receptor EP4 and subsequent
cyclic AMP (cAMP) production during the fetal period and that oxygen
constricts the DA by inhibiting potassium channels immediately after birth. In
addition to the regulation of vascular tone, morphological remodeling of the DA
throughout the perinatal period, such as prominent intimal thickening and poor
elastogenesis, has been demonstrated.
We recently identified the molecular mechanisms of the acquisition of unique
morphological remodeling in the DA during development. During the fetal
period, PGE2-EP4 signaling decreases elastic fiber formation through degrada-
tion of the cross-linking enzyme lysyl oxidase (LOX) and increases hyaluronan-
mediated intimal thickening in the DA. This remodeling is mediated by activa-
tion of the EP4 receptor via diverse downstream intracellular signaling
pathways. Hyaluronan-mediated intimal thickening was induced by the
EP4-Gs protein-cyclic AMP-protein kinase A pathway. The attenuation of
elastogenesis is mediated through a non-cyclic AMP signaling pathway, such
as c-src-phospholipase C (PLC). These data suggest that placental PGE2-
mediated vascular remodeling via different signaling pathways orchestrates the
subsequent luminal DA reorganization, leading to complete obliteration of
the DA.
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35.1 Introduction
The ductus arteriosus (DA) normally closes immediately after birth. Although the
DA is a normal and essential fetal structure, it becomes abnormal if it remains
patent after birth. DA closure occurs in two phases: functional closure of the lumen
in the first hours after birth by smooth muscle constriction and anatomic occlusion
of the lumen over the next several days due to extensive neointimal thickening in
human DA [1–3]. There are several events that promote DA constriction immedi-
ately after birth. Increasing oxygen tension and a dramatic decrease in circulating
PGE2 promote muscular constriction of the DA. In addition, DA remodeling is also
necessary for its complete closure. Remodeling is characterized by (a) an area of
subendothelial deposition of extracellular matrix [4], (b) the disassembly of the
internal elastic lamina and loss of elastic fiber in the medial layer [5], and
(c) migration into the subendothelial space of undifferentiated medial smooth
muscle cells (SMCs). Some of these changes begin about halfway through gesta-
tion, and some occur after functional closure of the DA in the neonate [3, 6]. In
addition to the well-known vasodilatory role of PGE2, our findings revealed the role
of PGE2 in the anatomical closure of the DA.
35.2 The Molecular Mechanisms of Intimal Thickening
of the Ductus Arteriosus
35.2.1 Hyaluronan-Mediated Intimal Thickening
PGE2 plays a primary role in maintaining the patency of the DA via its receptor EP4.
However, previous studies have demonstrated that genetic disruption of the PGE
receptor EP4 paradoxically results in fatal patent DA in mice [7, 8]. In addition,
double mutant mice in which cyclooxygenase (COX)-1 and COX-2 are disrupted also
exhibit patent DA [9]. We found that intimal thickening was completely absent in the
DA of EP4-disrupted neonatal mice [3]. Moreover, a marked reduction in hyaluronan
production was found in EP4-disrupted DA, whereas a thick layer of hyaluronan
deposit was present in wild-type DA. PGE2-EP4-cyclic AMP (cAMP)-protein kinase
A (PKA) signaling upregulates hyaluronan synthase type 2 mRNA, which increases
hyaluronan production in the DA. Accumulation of hyaluronan then promotes SMC
migration into the subendothelial layer to form intimal thickening [3].
EP4 is a Gs protein-coupled receptor that increases intracellular cAMP by
adenylyl cyclases (ACs) consisting of nine different isoforms of membrane-
bound forms of ACs (AC1 through AC9). We found that AC2 and AC6 are more
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highly expressed in rat DA than in the aorta during the perinatal period [10]. Our
data using AC subtype-targeted siRNAs and AC6-deficient mice suggest that AC6
is responsible for hyaluronan-mediated intimal thickening of the DA, whereas AC2
inhibits AC6-induced hyaluronan production. The activation of both AC2 and AC6
induces vasodilation.
35.2.2 Epac-Mediated SMC Migration
In addition to PKA, a new target of cAMP that is an exchange protein activated by
cAMP has recently been discovered; it is called Epac [11]. Epac is a guanine
nucleotide exchange protein that regulates the activity of small G proteins and
has been known to exhibit a distinct cAMP signaling pathway that is independent of
PKA [12]. There are two variants: Epac1 is expressed in most tissues, including the
heart and blood vessels, whereas Epac2 is expressed in the adrenal gland and the
brain. Although both Epac1 and Epac2 are upregulated during the perinatal period,
Epac1, but not Epac2, acutely promotes SMCmigration and thus intimal thickening
in the DA [13]. Since Epac stimulation does not increase hyaluronan production,
the effect of Epac1 on SMC migration is independent of that of hyaluronan
accumulation, which operates through a mechanism different from that underlying
PKA stimulation.
35.2.3 Regulation of Elastogenesis
Elastic fiber formation begins in mid-gestation and increases dramatically during
the last trimester in the great arteries. However, the DA exhibits lower levels of
elastic fiber formation [5], which may contribute to vascular collapse and
subsequent closure of the DA after birth. We found that EP4 significantly inhibited
elastogenesis and decreased lysyl oxidase (LOX) protein, which catalyzes elastin
cross-links in DA SMCs but not in aortic SMCs. In EP4-knockout mice, electron
microscopic examination showed that the DA acquired an elastic phenotype that
was similar to the neighboring aorta. More importantly, human DA and aorta
tissues from seven patients showed a negative correlation between elastic fiber
formation and EP4 expression, as well as between EP4 and LOX expression.
Together with in vitro experiments, these data suggest that PGE2-EP4 signaling
inhibits elastogenesis in the DA by degrading LOX protein. The EP4-cSrc-PLC-
γ-signaling pathway, a signaling pathway that has not previously been recognized,
most likely promoted the lysosomal degradation of LOX [14, 15].
35.3 Future Direction and Clinical Implications
The persistently patent DA after birth is a major cause of morbidity and mortality,
especially in premature infants, that can lead to severe complications, including
pulmonary hypertension, right ventricular dysfunction, postnatal infections, and
35 The Multiple Roles of Prostaglandin E2 in the. . . 255
respiratory failure [16]. The incidence of DA patency has been estimated to be 1 in
500 in term newborns [17]. In preterm babies with birth weights <1,500 g, the
incidence of patent DA exceeds 30 % [18]. Therefore, it is important to improve
current pharmacological therapy through understanding the precise mechanisms of
the regulation of the DA. Since both vascular contraction and remodeling are
required for complete DA closure, pharmacological therapies that promote vaso-
constriction and remodeling would be ideal for premature infants with persistently
patent DAs. On the other hand, vasodilation and inhibition of intimal thickening are
required for DA-dependent congenital heart diseases.
Our data suggest that PGE2-EP4-cAMP signaling promotes hyaluronan and
Epac-mediated intimal thickening and that the EP4-PLC pathway attenuates
elastogenesis in the DA. These cascades of events via different signaling pathways
are thought to orchestrate the subsequent luminal DA reorganization (Fig. 35.1),
Fig. 35.1 The diverse EP4 signaling pathways. Both PKA and Epac synergistically promoted
intimal cushion formation in the DA, but they work in two distinct ways. The cSrc-PLC pathway
inhibited elastogenesis via degrading LOX proteins
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leading to complete obliteration of the DA. In addition to its role in controlling
vascular tone in the functional closure of the DA, the vascular remodeling of the
DA is now attracting considerable attention as a target for novel therapeutic
strategies for patients with persistently patent DA and DA-dependent cardiac
anomalies.
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